Circulating Erythrocyte‐ and Endothelial‐Derived Microvesicles as Biomarkers of Hemolysis and Clinical Severity in Sickle Cell Disease
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70827 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Khouloud Khalfaoui und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular and Cellular Hematology (LMCH), Institut Pasteur de Tunis, Tunis, Tunisia. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Biomarkers, Hemolysis, Cell-Derived Microparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tunisian Ministry of Higher Education and Scientific Research.
Abstract (Originalsprache)
Sickle cell disease (SCD) is a monogenic disorder caused by the presence of hemoglobin S (Hb S) and is associated with a wide range of clinical complications, including hemolytic anemia, vaso‐occlusive crises (VOC), and acute chest syndrome (ACS). This variability is largely driven by Hb S polymerisation and abnormal cell adhesion, which promote the release of circulating microvesicles (MVs). MVs are small vesicles (0.1–1.0 μm) released from various cell types in response to oxidative stress, cellular activation, or apoptosis. They possess pro‐coagulant and pro‐inflammatory properties and are increasingly recognised as potential modulators of disease processes. In this study, homozygous SCD patients and healthy controls were recruited to characterise their MVs profiles using flow cytometry and to explore associations with clinical and biological parameters. SCD patients exhibited significantly elevated levels of MVs compared to controls. Notably, red cell–derived MVs (RMVs) and phosphatidylserine‐positive MVs (AMVs) were strongly associated with elevated lactate dehydrogenase (LDH) levels and clinical severity. A negative correlation was observed between fetal hemoglobin (Hb F) and endothelial MVs (EMVs), suggesting a protective role of Hb F against endothelial injury. These findings support the potential of MVs as diagnostic and prognostic biomarkers for identifying SCD patients at higher risk of complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular and Cellular Hematology (LMCH), Institut Pasteur de Tunis, Tunis, Tunisia.
- Laboratory of Bioinformatics, Biomathematics and Biostatistics (BIMS), Institut Pasteur de Tunis, Tunis, Tunisia.
- Higher Institute of Biotechnology of Béja, University of Jendouba, Jendouba, Tunisia.
- Department of Pediatrics: Immunology, Hematology, and Stem Cell Transplantation, National Bone Marrow Transplant Center, Tunis, Tunisia.
ORCID-Profile: Khouloud Khalfaoui
Förderung
- Tunisian Ministry of Higher Education and Scientific Research
Zitieren
APA
Khalfaoui, K., Chebbi, M., Souiai, O., Ben Fraj, I., Ben Khaled, M., Hableni, A., Barmate, M., Chaouachi, D., Mellouli, F., Ouederni, M., Safra, I., Menif, S., & Moumni, I. (2025). Circulating Erythrocyte‐ and Endothelial‐Derived Microvesicles as Biomarkers of Hemolysis and Clinical Severity in Sickle Cell Disease. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70827
Vancouver
Khalfaoui K, Chebbi M, Souiai O, Ben Fraj I, Ben Khaled M, Hableni A, et al. Circulating Erythrocyte‐ and Endothelial‐Derived Microvesicles as Biomarkers of Hemolysis and Clinical Severity in Sickle Cell Disease. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70827
BibTeX
@article{Khalfaoui2025,
author = {Khalfaoui, Khouloud and Chebbi, Mariem and Souiai, Oussema and Ben Fraj, Ilhem and Ben Khaled, Monia and Hableni, Amine and Barmate, Mbarka and Chaouachi, Dorra and Mellouli, Fethi and Ouederni, Monia and Safra, Ines and Menif, Samia and Moumni, Imen},
title = {Circulating Erythrocyte‐ and Endothelial‐Derived Microvesicles as Biomarkers of Hemolysis and Clinical Severity in Sickle Cell Disease},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70827}
}
EUVIMED